Search Results - enzyme

12 Results Sort By:
LIGHT CONTROLLED PROXIMITY LABELING WITH LOV-TURBO
LIGHT CONTROLLED PROXIMITY LABELING WITH LOV-TURBO Researchers at Stanford University have developed a new approach for proximity labeling via optogenetic control. Allosteric regulation is common in naturally occurring enzymes in living tissues. However, despite its ability to improve spatial and temporal control, allostery has yet to be used extensively...
Published: 7/6/2023   |   Inventor(s): Joleen Cheah, Alice Ting, Songyi Lee
Keywords(s): Allostery, Enzyme, Optogenetics, Protein Engineering, Proximity Labeling
Category(s): Technology Classifications > Biology
Nucleic Acid Primers and Probes for Detecting Ebola Virus (species Zaire ebolavirus)
The 2014-2016 Ebola Virus Disease (EVD) outbreak in West Africa was the largest in history, causing more than 28,000 suspected, probable, and confirmed infections and more than 11,000 deaths across nine countries. CDC scientists designed nucleic acid primers and probes which can be used in a sensitive test for detecting all known strains of Ebola virus...
Published: 10/28/2024   |   Inventor(s): Tara Sealy, Ute Stroeher, Stuart Nichol, Jonathan Towner
Keywords(s): 7, Acid, antibodies, ANTIGENS, assay, DETECTING, Detection, Ebola, Ebolavirus, ELISA, Enzyme, Identification, immunosorbent, LINKED, Listed LPM Kirby as of 4/15/2015, Mab, monoclonal, Mouse, NCEZID, NCEZID-DHCPP, Nucleic, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRIMERS, Probes, Species, Used, virus, Viruses, Zaire
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing
Novel One-Well Limiting-Antigen Avidity Enzyme Immunoassay to Detect Recent HIV-1 Infection Using a Multi-subtype Recombinant Protein
This CDC developed Limiting-Antigen avidity Enzyme Immunoassay (LAg-avidity-EIA) provides an easy way to measure increasing binding strength (avidity) of HIV antibodies as part of maturation HIV antibodies after seroconversion, providing a method to distinguish early-stage from long-term HIV-1 infection. Surveillance of HIV-1 provides information on...
Published: 10/28/2024   |   Inventor(s): Bharat Parekh
Keywords(s): AA5XXX, AAXXXX, Avidity, Avidity-EIA, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CGH-DGHA, DA4AXX, DA4XXX, DAXXXX, DDXXXX, Detect, Development, DXXXXX, Enzyme, HIV, IMMUNOASSAY, Infection, Inmunoassay, LAg, Limiting-antigen, Listed LPM Houze as of 4/15/2015, Multi-subtype, NCHHSTP, One-well, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RECENT, recombinant, RIDR-M, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Consumer Products, TherapeuticArea > Immunology, Application > Diagnostics, ResearchProducts > Antibodies, Application > Therapeutics, Application > Occupational Safety and Health, Application > Research Materials
Human DNA Polymerase Gamma for Testing the Effect of Drugs on Mitochondrial Function
One of the primary means for treating HIV infection is the use of antiviral nucleotide or nucleoside analogs. These analogs work by inhibiting the activity of reverse transcriptase, the enzyme responsible for preparing the HIV genome for integration into the DNA of the host cell. Although these analogs do not have an effect on the polymerases responsible...
Published: 10/28/2024   |   Inventor(s): Rajesh Kasiviswanathan, Susan Lim, William Copeland
Keywords(s): CLONE, DDXXXX, DEFICIENT, Directed, DNA, DXXXXX, Enzyme, EXONUCLEASE, Expression, Gamma, Human, Improved, Includes, Listed LPM Campbell as of 4/15/2015, Method, Modifications, polymerase, Polymerase., Post LPM Assignment Set 20150420, Pre LPM working set 20150418, purification, recombinant, RXXXXX, SITE, TYPE, VLXXXX, Which, Wild, WIXXXX, XEXXXX, YBXXXX
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Therapeutics
Modulating Autophagy as a Treatment for Lysosomal Storage Diseases
Researchers at NIAMS have developed a technology for treatment of lysosomal storage diseases by inhibition of autophagy. Pompe disease is an example of a genetic lysosomal storage disease caused by a reduction or absence of acid alpha-glucosidase (GAA). Patients with Pompe disease have a lysosomal buildup of glycogen in cardiac and skeletal muscle...
Published: 8/14/2024   |   Inventor(s): Cynthia Schreiner, Paul (Estate of) Plotz, Shoichi Takikita, Tao Xie, Rebecca Baum, Nina Raben
Keywords(s): Acid, A-glucosidase, Autophagy, B, Clearance, Complete, DEFICIENCY, Disabling, Disease, Enzyme, ERT, GB1XXX, GBXXXX, Genetic, GLYCOGEN, GXXXXX, IBXXXX, Inactivation, IXXXXX, Lysosomal, Model, Mouse, MUSCLE, Near, Patent Category - Biotechnology, Permits, Pompe, REPLACEMENT, SKELETAL, Storage, STORED, THERAPY, UA1XXX
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, Application > Research Materials
ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation
ADP-ribosylation is important in many cellular processes, including DNA replication and repair, maintenance of genomic stability, telomere dynamics, cell differentiation and proliferation, and necrosis and apoptosis. Poly-ADP-ribose is important in a number of critical physiological processes such as DNA repair, cellular differentiation, and carcinogenesis....
Published: 10/28/2024   |   Inventor(s): Joel Moss
Keywords(s): Activity, Alpha-NAD, Alpha-NADase, ARH3, CB6XXX, CBXXXX, Cell, CXXXXX, Enzyme, Hydrolase:, IB6XXX, IBXXXX, Ihe, IXXXXX, LEVELS, Maintenance, MAMMALIAN, MAY, PAR, PARG-like, Patent Category - Biotechnology, Poly-ADP-ribose, RELEVANT
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Reproductive Health, Application > Diagnostics, Application > Research Materials
Novel Pharmaceutical for Prevention of Bleomycin-Induced Pulmonary Fibrosis
Reference #: 01409 The University of South Carolina is offering licensing opportunities for Novel Pharmaceutical for Prevention of Bleomycin-Induced Pulmonary Fibrosis Background: Hodgkin’s lymphoma is one of the curable cancers and the standard treatment regimen involves combination chemotherapy involving bleomycin. One of the fatal side effects...
Published: 9/4/2022   |   Inventor(s): Michael Wyatt, Chloe LeBegue
Keywords(s): bleomycin, bleomycin hydrolase, enzyme, inhaled, protein, pulmonary fibrosis, pulmonary toxicity, pulmonology biotech, pulmonology pharma
Category(s): Chemistry and Biochemistry, Health Sciences
Thermostable, Solvent-Tolerant Biocatalyst for Extreme Conditions
Haloarchaeal Inorganic Pyrophosphatase Operates in a Variety of Solvents to Aid DNA Sequencing, PCR, SNP Genotyping, and RNA Synthesis This biocatalyst, or enzyme, accelerates organic synthesis reactions in extreme conditions that available biocatalysts do not tolerate. This thermostable inorganic pyrophosphatase (PPA) developed by University of Florida...
Published: 2/22/2024   |   Inventor(s): Julie Maupin, Nathaniel Hepowit, Lana McMillan
Keywords(s): Biocatalyst, Biotech, Biotechnology, Dna Sequencing, Enzyme, Heat Stable, Inorganic pyrophosphatase, organic synthesis reactions, PCR, RNA synthesis, single-base-extension, SNP genotyping, solvent-tolerant, Thermostable
Category(s): Technology Classifications > Research Tools > Others
Potent Compounds for the Treatment of Canavan Disease & Cancers
Project ID: D2016-55Invention Description:Elevated levels of N-acetylaspartate (NAA) is a major hallmark of Canavan disease (CD), which currently has no cure or standard course of treatment. Mutations in the aspA gene, which encodes aspartoacylase, render it unable to adequately catalyze the synthesis of NAA in CD patients. The Nat8l gene encodes aspartate...
Published: 10/29/2024   |   Inventor(s): Ronald Viola, Bharani Thangavelu, Qinzhe Wang, Vinay Mutthamsetty
Keywords(s): Canavan, Cancer, Enzyme, Inhibitor, Neurological, Target
Category(s): Rare Disease
Inhibitors of the ubiquitin E3 ligase BCA2 as anti-cancer therapeutic agents
Background:Breast cancer associated protein 2 (BCA2) is a ubiquitin E3 ligase found in invasive breast cancer. Studies have shown that by decreasing its activity, breast cancer cell growth and invasiveness are diminished. Targeting this ligase and inhibiting its activity could play a role in treatment of breast cancer. A molecular approach to inhibiting...
Published: 3/12/2018   |   Inventor(s): Angelika Burger, Andrew Westwell
Keywords(s): Analog or Analogue, Breast Cancer, Cancer, Disease, Drug Target, Enzyme
Category(s): Diseases, Oncology, Therapeutics, Life Science, Research tools
1 2